Navigation Links
CHPA Applauds New Mexico Adoption Of House Bill 146

WASHINGTON, March 16, 2013 /PRNewswire-USNewswire/ -- The Consumer Healthcare Products Association (CHPA) today applauded the New Mexico legislature for passing House Bill 146, an anti-methamphetamine bill authored by Representative Antonio "Moe" Maestas (D-16).  Once Governor Susana Martinez (R-N.M.) signs the bill into law, New Mexico will become the 27th state to adopt electronic pseudoephedrine (PSE) sales blocking technology.

Real-time, stop-sale technology is a proven and powerful tool that allows retailers and pharmacists to block unlawful attempted purchases of cold and allergy medicines containing PSE that exceed daily or monthly limits established by the 2005 Combat Methamphetamine Epidemic Act. While law-abiding consumers make the vast majority of PSE purchases, some hardened criminals illegally obtain these products in order to manufacture meth. Illegal sales blocking technology empowers retailers and law enforcement officials with the ability to track and block illegal sales of products containing PSE before they happen. Before this technology was in place, retailers had to manually record PSE purchases in a hand-written logbook—a cumbersome and ineffective system for preventing unlawful sales. Real-time, stop-sale technology is also a useful tool for police officers and narcotics agents. Law enforcement officials have instant access to PSE purchasing activity which can help determine if a suspect is purchasing PSE in order to manufacture meth.. The system is provided at no charge to the state.

"Shortly after Governor Martinez signs this important legislation into law, more than half the nation will be covered by pseudoephedrine tracking technology," said Scott Melville , president and chief executive officer of the Consumer Healthcare Products Association. "In addition to New Mexico, twenty-six states have chosen to adopt real-time, stop-sale technology because in addition to providing an exceptional resource to law enforcement and retailers, the technology ensures that law-abiding consumers continue to have access to the cold and allergy medicines they know and trust. More than 18 million American families rely on safe and effective medicines containing pseudoephedrine for relief from symptoms. We commend Representative Maestas for advancing legislation that targets criminals, not responsible New Mexico taxpayers."

CHPA is the 132-year-old-trade association representing U.S. manufacturers and distributors of over-the-counter medicines and dietary supplements.

SOURCE Consumer Healthcare Products Association
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Applauds GPhA Study Demonstrating $1 Trillion in Prescription Drug Savings from Generic Medicines
2. Mylan Applauds Study Highlighting $1 Trillion in Savings for U.S. Health Care System Due to Generic Drugs Over Past Decade
3. CRN Applauds Introduction Of Designer Anabolic Steroid Control Act
4. ADVENTRX Applauds Inclusion of Rare Diseases Provisions in the FDA Safety and Innovation Act
5. Mylan Applauds Signing of Landmark "Food and Drug Administration Safety and Innovation Act"
6. American Academy of Pain Medicine Applauds FDA Action to Enhance Patient Safety on Prescribing Opioids; Offers AAPM Safe Opioid Prescribing Course as Educational Model
7. Novation Applauds FDAs Unique Device Identification Rule
8. Obesity Care Continuum (OCC) Applauds FDA for Approval of New Obesity Drug
9. Omega Laboratories Applauds the Adoption of Enzyme Immunoassay (EIA) by Major Hair Testing Laboratories
10. CHPA Applauds Arizonas Adoption Of HB 2263
11. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
Post Your Comments:
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/26/2016)... ... 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing ... their videos a whole new perspective by using the title layers in ProSlice ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
Breaking Medicine News(10 mins):